Tyrosine kinase inhibitor
|
T651028-25mg
|
≥99% |
1021950-26-4 |
25mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |
Tyrosine kinase inhibitor
|
T651028-10mg
|
≥99% |
1021950-26-4 |
10mg
|
¥ 4300.9
|
期货,请咨询 |
阿拉丁 |
Tolonidine
|
T651017-5mg
|
≥99% |
4201-22-3 |
5mg
|
¥ 2100.9
|
期货,请咨询 |
阿拉丁 |
Tolonidine
|
T651017-10mg
|
≥99% |
4201-22-3 |
10mg
|
¥ 3600.9
|
期货,请咨询 |
阿拉丁 |
TRPC6-IN-3
|
T650957-5mg
|
≥99% |
2311863-36-0 |
5mg
|
¥ 8500.9
|
期货,请咨询 |
阿拉丁 |
TRPC6-IN-3
|
T650957-50mg
|
≥99% |
2311863-36-0 |
50mg
|
¥ 48500.9
|
期货,请咨询 |
阿拉丁 |
TRPC6-IN-3
|
T650957-25mg
|
≥99% |
2311863-36-0 |
25mg
|
¥ 30000.9
|
期货,请咨询 |
阿拉丁 |
TRPC6-IN-3
|
T650957-10mg
|
≥99% |
2311863-36-0 |
10mg
|
¥ 14500.9
|
期货,请咨询 |
阿拉丁 |
TRPC6-IN-3
|
T650957-100mg
|
≥99% |
2311863-36-0 |
100mg
|
¥ 76000.9
|
期货,请咨询 |
阿拉丁 |
TAK-615
|
T650935-5mg
|
≥99% |
1664335-55-0 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
TAK-615
|
T650935-50mg
|
≥99% |
1664335-55-0 |
50mg
|
¥ 14500.9
|
期货,请咨询 |
阿拉丁 |
TAK-615
|
T650935-25mg
|
≥99% |
1664335-55-0 |
25mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
TAK-615
|
T650935-10mg
|
≥99% |
1664335-55-0 |
10mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |
TAK-615
|
T650935-100mg
|
≥99% |
1664335-55-0 |
100mg
|
¥ 22500.9
|
期货,请咨询 |
阿拉丁 |
TD52
|
T650928-5mg
|
≥95% |
1798328-24-1 |
5mg
|
¥ 850.9
|
期货,请咨询 |
阿拉丁 |
TD52
|
T650928-50mg
|
≥95% |
1798328-24-1 |
50mg
|
¥ 5500.9
|
期货,请咨询 |
阿拉丁 |
TD52
|
T650928-25mg
|
≥95% |
1798328-24-1 |
25mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
TD52
|
T650928-10mg
|
≥95% |
1798328-24-1 |
10mg
|
¥ 1600.9
|
期货,请咨询 |
阿拉丁 |
TD52
|
T650928-100mg
|
≥95% |
1798328-24-1 |
100mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
TRPM8 antagonist 3
|
T650908-5mg
|
≥99% |
2102179-29-1 |
5mg
|
¥ 2800.9
|
期货,请咨询 |
阿拉丁 |
TRPM8 antagonist 3
|
T650908-50mg
|
≥99% |
2102179-29-1 |
50mg
|
¥ 13000.9
|
期货,请咨询 |
阿拉丁 |
TRPM8 antagonist 3
|
T650908-25mg
|
≥99% |
2102179-29-1 |
25mg
|
¥ 8700.9
|
期货,请咨询 |
阿拉丁 |
TRPM8 antagonist 3
|
T650908-10mg
|
≥99% |
2102179-29-1 |
10mg
|
¥ 4300.9
|
期货,请咨询 |
阿拉丁 |
1,1,3-Tribromoacetone
|
T650894-500mg
|
|
3475-39-6 |
500mg
|
¥ 910.9
|
期货,请咨询 |
阿拉丁 |